Noile-Immune Biotech Inc
4893
Company Profile
Business description
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
Contact
2-12-10 Shiba-Daimon
5th Floor, T&G Hamamatsucho Building
Minato-ku
Yamaguchi
Tokyo105-0012
JPNT: +81 358437819
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.70 | 45.90 | 0.50% |
| CAC 40 | 8,255.66 | 57.46 | -0.69% |
| DAX 40 | 25,252.99 | 99.40 | -0.39% |
| Dow JONES (US) | 49,387.86 | 54.58 | -0.11% |
| FTSE 100 | 10,228.06 | 10.88 | -0.11% |
| HKSE | 26,844.96 | 78.66 | -0.29% |
| NASDAQ | 23,575.63 | 45.61 | 0.19% |
| Nikkei 225 | 53,936.17 | 174.33 | -0.32% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,949.26 | 4.79 | 0.07% |
| S&P/ASX 200 | 8,903.90 | 48.10 | 0.54% |
| SSE Composite Index | 4,101.91 | 10.69 | -0.26% |